Syntara Limited · ASX:SNT
Syntara — Q4 2023 Earnings Presentation
9 slides from Syntara's earnings presentation, Feb 1, 2024
Slide 1: Shareholder Update; Q4 2023
For personal use only ™ Shareholder Update; Q4 2023 Gary Phillips, CEO 1st February 2024
Slide 2: Forward looking statement
Forward looking statement For personal use only This document contains involve known and unknown forward-looking statements, risks, uncertainties and other including statements factors, many of which are concerning Syntara’s future beyond our control, and which financial position, plans, and may cau
Slide 3: Highlights from December Quarter 2023
Highlights from December Quarter 2023 • Closed sale agreement for mannitol business unit For personal use only • Securing more than $14m reduction in costs per annum • Low double digit royalty on profit from mannitol business • Successful capital raise of $10m • Second of two tranche placement appro
Slide 4: Myelofibrosis
Myelofibrosis A rare type of bone marrow cancer that disrupts the body's normal production of blood cells For personal use only Key Facts Primary Myelofibrosis is Current standard SNT-5505 characterised by a build up of scar of care (SoC): JAK inhibition In contrast to SoC tissue (fibrosis) in bone
Slide 5: Phase 2a study cohort added to trial SNT-5505 in patients on a stable dose of JAK inhibitor
Phase 2a study cohort added to trial SNT-5505 in patients on a stable dose of JAK inhibitor Fastest route to meaningful data with no dose escalation and utilizing existing trial Study Plan For personal use only infrastructure • 20 clinical trial sites scheduled to be open for Study recruitment by De
Slide 6: Potential to deliver near term value
Potential to deliver near term value Pipeline creates multiple opportunities in high value markets Drug Upcoming Addressable For personal use only Indication Phase Trial design Status Candidate Milestones market (US$) • Open label 12 month study (n=15) First H2 2024: • MF patients receiving a stable
Slide 7: News flow
News flow Recent and anticipated news flow Strong and growing pipeline with advancement in For personal use only studies expected to provide value inflection points Q4 2023 H1 2024 H2 2024 • SNT-5505 phase 2a myelofibrosis • Pan-LOX scar prevention for burn • SNT-5505 phase 2a combination study (add
Slide 8: Shareholders & Cash
Shareholders & Cash For personal use only Financial Information 31 Jan 242 Institutional Ownership2 31 Jan 24 ASX Code SNT BVF Partners LP 12% D&A Income Limited 10% Share price $0.019 Platinum Investment Management 8% Limited Market Cap A$16m Total Institutional Ownership 47% Proforma cash balance
Slide 9: For personal use only
For personal use only Gary Phillips Syntara Limited ABN 75 082 811 630 Chief Executive Officer gary.phillips@syntaraTX.com.au David McGarvey Chief Financial Officer david.mcgarvey@syntaraTX.com.au www.syntaraTX.com.au